Pharmacotherapeutic group: Macrolides, ATCvet code: QJ01FA90
Tylosin is a macrolide antibiotic produced by a strain of Streptomyces fradiae. It exerts its antimicrobial effect by inhibiting protein synthesis of susceptible micro-organisms.
The tylosin spectrum of activity includes Gram-positive bacteria including Clostridium perfringens and some Gram-negative strains such as Pasteurella and Mycoplasma spp. at concentrations of 16µg/ml or less.
Absorption: Tylosin reaches maximal blood levels between 1 and 3 hours after an oral dose. Minimal or no blood levels remain 24 hours after an oral dose.
Distribution: After oral doses were given to pigs, tylosin was found in all tissues, between 30 minutes and two hours after administration, except for the brain and spinal cord.
Biotransformation and Elimination: It has been shown that most of the material which is excreted is to be found in the faeces and consists of tylosin (factor A), relomycin (factor D) and dihydrodesmycosin.